Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Oryzon Genomics SA ( (ES:ORY) ) has provided an announcement.
Oryzon Genomics SA has announced the convening of its Ordinary General Meeting of Shareholders, scheduled for June 27, 2025, in Madrid. The meeting will address several key agenda items, including the approval of the annual accounts and management report for the fiscal year ending December 31, 2024, and the application of the fiscal year’s results. This meeting is significant for stakeholders as it will cover crucial financial and operational decisions that could impact the company’s strategic direction and shareholder interests.
The most recent analyst rating on (ES:ORY) stock is a Buy with a EUR2.30 price target. To see the full list of analyst forecasts on Oryzon Genomics SA stock, see the ES:ORY Stock Forecast page.
More about Oryzon Genomics SA
Oryzon Genomics SA operates in the biotechnology industry, focusing on the development of epigenetic therapies. The company is engaged in research and development of therapeutic products for various medical conditions, leveraging its expertise in gene regulation and epigenetics to create innovative treatments.
YTD Price Performance: 91.07%
Average Trading Volume: 1,068,944
Technical Sentiment Signal: Buy
Current Market Cap: €207.3M
Find detailed analytics on ORY stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue